Concepedia

Nizar M. Tannir

NM

295

Publications

27.9K

Citations

80

H-Index

1983

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Institut Gustave Roussy

Bristol-Myers Squibb (United States)

Nizar M. Tannir is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and urology.

Top concepts

MedicineOncologyUrologyCancer TherapyRadiation OncologyCancer ResearchMolecular OncologyPathologySurgical OncologyPharmacotherapy

Publications per year

1983–2025

295

Publications

295

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera et al. · New England Journal of Medicine · 2018 · 4.5K citations · Full text

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +11

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · New England Journal of Medicine · 2015 · 1.2K citations · Full text

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · The Lancet Oncology · 2016 · 927 citations · Full text

Urology, Genitourinary Cancer, Kidney Research +8

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 763 citations · Full text

Urology, Genitourinary Cancer, Medicine +8

Rows per page

1–5 of 295